AN2 Therapeutics, Inc.
AN2 Therapeutics is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from boron chemistry. They aim to address high unmet needs in global health by developing boron-based compounds for infectious diseases and oncology, with a commitment to global health initiatives and collaboration with public and private organizations.
Industries
Nr. of Employees
small (1-50)
AN2 Therapeutics, Inc.
Menlo Park, California, United States, North America
Products
AN2-502998
Boron-based small-molecule therapeutic candidate in IND‑enabling development for chronic Trypanosoma cruzi (Chagas disease); reported preclinical curative activity across multiple species including non-human primates.
Epetraborole
Orally available boron-containing small-molecule inhibitor of bacterial leucyl-tRNA synthetase under clinical development for serious bacterial infections (including melioidosis and nontuberculous mycobacterial lung disease); subject of Phase 1 and Phase 2 clinical studies and multiple preclinical evaluations.
AN2-502998
Boron-based small-molecule therapeutic candidate in IND‑enabling development for chronic Trypanosoma cruzi (Chagas disease); reported preclinical curative activity across multiple species including non-human primates.
Epetraborole
Orally available boron-containing small-molecule inhibitor of bacterial leucyl-tRNA synthetase under clinical development for serious bacterial infections (including melioidosis and nontuberculous mycobacterial lung disease); subject of Phase 1 and Phase 2 clinical studies and multiple preclinical evaluations.
Services
Collaborative development and licensing partnerships
Collaboration, licensing, and regional development arrangements to enable external development, manufacturing, and commercialization of development-stage compounds.
Collaborative preclinical and translational research partnerships
Partnerships to support preclinical efficacy testing, in vitro susceptibility testing, PK/PD analyses, and IND-enabling studies for infectious disease programs.
Collaborative development and licensing partnerships
Collaboration, licensing, and regional development arrangements to enable external development, manufacturing, and commercialization of development-stage compounds.
Collaborative preclinical and translational research partnerships
Partnerships to support preclinical efficacy testing, in vitro susceptibility testing, PK/PD analyses, and IND-enabling studies for infectious disease programs.
Expertise Areas
- Boron-based small-molecule drug discovery
- Antibacterial and antiparasitic therapeutic development
- Preclinical translational research and multi-species efficacy testing
- PK/PD analysis and population pharmacokinetic modeling
Key Technologies
- Boron-containing small molecules
- Reversible covalent target engagement
- Computational chemistry for small-molecule design
- Medicinal chemistry and SAR optimization